<a href="https://www.fiercebiotech.com/biotech/orukas-psoriasis-data-hailed-outright-win-over-skyrizi-spurring-big-blockbuster-forecasts" hreflang="en">Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts</a>
Oruka Therapeutics' psoriasis treatment, ORKA-001, demonstrated significant efficacy in a phase 2a trial, achieving complete skin clearance in 63.5% of patients, which analysts predict could lead to sales of up to $10 billion, surpassing AbbVie's Skyrizi. The promising results, including a potential for annual dosing, have prompted Oruka to prepare for a phase 3 trial.
Oruka Therapeutics' ORKA-001 has shown unprecedented efficacy in a phase 2a trial for plaque psoriasis, surpassing AbbVie's Skyrizi in skin clearance rates with a potential for annual dosing. This positions ORKA-001 as a strong contender in the IL-23 inhibitor space, potentially generating $5 billion to $10 billion in sales, making it a significant asset for stakeholders interested in investing in innovative biotech solutions with a promising market trajectory.